RJA
ODT

Raymond James & Associates’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Raymond James & Associates’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-9,820
Closed -$416K – 3733
2020
Q2 		$416K Sell
9,820
-988
-9% -$32K ﹤0.01% 2717
2020
Q1 		$298K Sell
10,808
-195
-2% -$5.68K ﹤0.01% 2780
2019
Q4 		$357K Buy
11,003
+1,698
+18% +$52.6K ﹤0.01% 2977
2019
Q3 		$242K Buy
+9,305
New +$311K ﹤0.01% 3139

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Raymond James & Associates's ODT Position: Q3 2020 in Review

Raymond James & Associates sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q3 2020, closing a stake of 9,820 shares — an estimated $416K sold.

Raymond James & Associates first reported a position in ODT in Q3 2019 and held it in 4 quarters. The position peaked at $416K in Q2 2020. 89 funds tracked by Wall St. Rank hold ODT as of Q3 2020.

  • Raymond James & Associates reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Raymond James & Associates sold 9,820 Odonate Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $416K.
  • Raymond James & Associates first reported a position in Odonate Therapeutics, Inc. Common Stock in Q3 2019 and held it in 4 quarters.
  • Raymond James & Associates's Odonate Therapeutics, Inc. Common Stock position peaked at $416K in Q2 2020.
  • 89 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Raymond James & Associates's 13F filing for Q3 2020, filed 4 Nov 2020.